Lingohr Asset Management GmbH Decreases Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Lingohr Asset Management GmbH decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 90.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 900 shares of the medical research company’s stock after selling 8,068 shares during the quarter. Lingohr Asset Management GmbH’s holdings in Thermo Fisher Scientific were worth $365,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of TMO. Bernard Wealth Management Corp. purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at $25,000. CBIZ Investment Advisory Services LLC raised its stake in shares of Thermo Fisher Scientific by 137.5% in the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 33 shares during the period. Ameriflex Group Inc. purchased a new stake in shares of Thermo Fisher Scientific in the fourth quarter valued at $30,000. Anderson Financial Strategies LLC purchased a new stake in shares of Thermo Fisher Scientific in the first quarter valued at $30,000. Finally, Keystone Global Partners LLC purchased a new stake in shares of Thermo Fisher Scientific in the first quarter valued at $31,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president owned 22,367 shares of the company’s stock, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the sale, the chief executive officer directly owned 115,174 shares in the company, valued at $57,697,567.04. The trade was a 7.99% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 30,066 shares of company stock valued at $14,182,963. 0.33% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the stock. Barclays upgraded shares of Thermo Fisher Scientific from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $490.00 to $550.00 in a report on Thursday. Royal Bank Of Canada set a $561.00 price target on shares of Thermo Fisher Scientific and gave the stock an “outperform” rating in a report on Tuesday, September 2nd. UBS Group upped their price target on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a “neutral” rating in a report on Thursday, July 24th. Evercore ISI cut their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an “outperform” rating on the stock in a report on Tuesday, July 8th. Finally, Scotiabank upgraded shares of Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 price target on the stock in a report on Friday, July 11th. Seventeen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and a consensus target price of $592.24.

Thermo Fisher Scientific Stock Performance

TMO stock opened at $479.48 on Monday. The firm has a market cap of $181.06 billion, a price-to-earnings ratio of 27.73, a PEG ratio of 2.56 and a beta of 0.75. The firm has a 50-day simple moving average of $466.86 and a two-hundred day simple moving average of $450.58. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $623.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. The firm had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific’s revenue was up 2.9% on a year-over-year basis. During the same period last year, the firm posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.